Qualicaps competitors

Dr. Thomas J. Schall is the founder of our company and has served as our President, Chief Executive Officer and Director since we commenced operations in 1997 and was appointed Chairman of the Board in April 2012. From 1993 to 1997, Dr. Schall worked at the DNAX Research Institute, a division of Schering-Plough Corporation, a pharmaceutical company. Prior to his work at the DNAX Research Institute, he worked as a scientist with Genentech, Inc., a pharmaceutical company. Dr. Schall participated in some of the earliest discoveries of chemokine system function and activities. Dr. Schall cloned one of the first chemokines to be discovered, and provided some of the earliest data for the existence of the previously unknown family of molecules which later came to be called the chemokines. Dr. Schall's laboratories have been responsible for the discovery or co-discovery of a large percentage of all known chemokine receptors. Dr. Schall received his B.S. in biology from Northern Illinois University and his Ph.D. in cancer biology from Stanford University.

Eric has served as President and Chief Executive Officer since April 2015. In an effort to expand West’s global footprint, grow its integrated drug containment and delivery product offerings, and take steps to optimize its manufacturing network, Eric launched West’s new organizational structure and strategy in the beginning of 2016. Prior to joining West, Eric served as Executive Vice President and President for the Research Markets business unit for Sigma-Aldrich Corporation, where he gained extensive international experience, serving in a number of regional, commercial and operational leadership roles over his more than 20-year career there. Eric earned his Master of Business Administration from the Olin Business School-Washington University and bachelor’s degree in chemistry from Bethel University. Eric also serves as a member of Bethel University’s Board of Trustees.